Assessment of Grazax® Treatment Compliance

A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00293046

Enrollment

500

Registered

2006-02-17

Start date

2006-02-28

Completion date

2007-10-31

Last updated

2008-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Keywords

Allergy

Brief summary

This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Interventions

BIOLOGICALALK Grass tablet - use of compliance device

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Grass pollen induced rhinoconjunctivitis * Males and females, 18-65 years of age * Positive skin prick test

Exclusion criteria

* Previous treatment with grass pollen allergen

Design outcomes

Primary

Measure	Time frame
Assessment of treatment compliance by recording of drug accountability	—

Secondary

Measure	Time frame
Recording of adverse events	—

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026